# A Study to Examine APL-130277 in Patients With Parkinson's Disease

> **NCT02228590** · PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** APL-130277

## Key facts

- **NCT ID:** NCT02228590
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-31
- **Primary completion:** 2014-11-24
- **Final completion:** 2014-11-24
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02228590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02228590, "A Study to Examine APL-130277 in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02228590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*